TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

NCT04592029 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

DRUG: TACE combined with sintilimab and bevacizumab

Sponsor

Second Affiliated Hospital of Guangzhou Medical University